The first FDA-approved MASH drug doesn’t treat patients with liver cirrhosis. A new Boehringer Ingelheim/Ochre Bio collaboration is researching regenerative medicines that could treat patients in this most advanced stage of the fatty liver disease.
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
AstraZeneca subsidiary and California-based firm to develop AAV-based therapy for chronic lung disease.